Alterity Therapeutics Ltd. (PRNAF)
OTHER OTC:PRNAF
Want to see PRNAF full AI Analyst Report?
PRNAF Stock Chart & Stats
$0.01
>-$0.01(-47.06%)
At close: 4:00 PM EDT
$0.01
>-$0.01(-47.06%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume10.00K
Average Volume (3M)36.00
Market Cap
$86.77M
Enterprise Value$70.59M
Total Cash (Recent Filing)$49.20M
Total Debt (Recent Filing)$163.91K
Price to Earnings (P/E)―
Beta4.77
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume0
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue18.42
Enterprise Value/Gross Profit19.02
Enterprise Value/Ebitda-3.51
Forecast
1Y Price Target
<$0.01Price Target Upside-27.89% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$2.36M
Bulls Say, Bears Say
Bulls Say
Proprietary PipelineAlterity's focus on proprietary small-molecule iron‑modulating compounds and a lead clinical program in MSA provides a durable technical moat. Ownership of core chemistry and a targeted clinical strategy supports longer-term licensing, partnership and value creation through clinical milestones rather than transient market moves.
Top-line GrowthA 46% revenue increase demonstrates durable top-line momentum that can support sustained R&D and trial progression. Persistent revenue growth improves runway management and bargaining power with partners and funders, reducing execution risk over the next several quarters if trends continue.
Very Low LeverageMinimal financial leverage gives Alterity structural flexibility to manage long clinical timelines and absorb trial setbacks. A strong equity base reduces bankruptcy risk and preserves capacity to raise non-debt capital, a durable advantage in capital-intensive biotech development.
Bears Say
Negative Cash FlowSustained negative operating and free cash flow and a -30% FCF growth rate signal ongoing cash burn. Over months this necessitates external financing, increasing dilution or forcing cost cuts that can delay trials and erode long-term R&D momentum if not addressed.
Unprofitable OperationsNegative ROE alongside reported net and EBIT margins below zero indicates the company cannot currently convert revenue into shareholder returns. Persistent unprofitability undermines internal capital generation and heightens reliance on external funding, affecting sustainable growth prospects.
Reliance On Capital Raises & Small ScaleWith no recurring product revenue and dependence on equity financings, Alterity faces structural funding risk. Combined with a very small headcount (10 employees), this constrains operational scale, increases execution risk for trials, and raises the likelihood of dilution over the medium term.
Alterity Therapeutics News
PRNAF FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is $86.77M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 298 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported >-$0.001 earnings per share for the quarter, the consensus estimate of >-$0.001 by $0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of >-$0.001 in its last earnings report, expectations of >-$0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in PRNAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
<$0.01 (-27.89% Downside)
<$0.01 (-27.89% Downside)
Blogger Sentiment
Bullish
PRNAF Sentiment 96%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
PRNAF Stock 12 Month Forecast
Average Price Target
<$0.01
▼(-27.89% Downside)
Technical Analysis
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―
Ownership Overview
0.21%
Insiders
―
Mutual Funds
― Other Institutional Investors
99.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---